Local anesthetic systemic toxicity is the complication injectors calculate for and then fail to recognise. The calculation is the easy half — a weight, a concentration, two operations, and you have a ceiling. The hard half is that LAST does not wait for you to reach the ceiling, it does not announce itself with anything dramatic, and the window in which it is easy to manage is occupied by symptoms so vague that the patient may not mention them and the injector may not ask.
This article is about recognition. Not the dose ceiling, which is covered separately in this cluster, and not agent selection, which is covered separately as well. Recognition — what the prodrome actually is, what it looks like in an aesthetic chair specifically, and what you do in the first sixty seconds.
The cascade, as it is classically taught
Dr. Thomas-Goering teaches the cascade in a fixed order, and it is worth committing to memory because it is the mental model that makes the early signs mean something:
- Numbness or tingling around the mouth or face — perioral or circumoral paraesthesia. This is first.
- Tinnitus — ringing in the ears. Auditory changes generally.
- Lightheadedness, dizziness and confusion.
- Seizures.
- Cardiovascular collapse.
The published description adds two symptoms to the front of that list that are worth knowing because patients volunteer them spontaneously: a metallic taste, and agitation or disinhibition — a patient who becomes oddly talkative, restless or uncharacteristically anxious.
The underlying logic is a sensitivity difference: the central nervous system is more sensitive to local anesthetic than the cardiovascular system is. The plasma concentration that produces CNS symptoms is lower than the concentration that produces cardiac toxicity. That is the whole reason a prodrome exists at all, and it is why CNS toxicity is the most common and usually the initial presentation — reported in roughly 68% to 77% of cases in a registry review.
At the cardiovascular end, the sequence itself has two phases that are easy to misread: an excitatory phase of hypertension, tachycardia and ventricular arrhythmias, followed by a depressant phase of bradycardia, conduction block, reduced contractility, hypotension and asystole. A patient whose blood pressure is rising is not reassuringly stable.
Two rules that follow from the cascade
The cascade is the mental model. These are the two operating rules I want you to take from it, and the second one is the one that gets missed.
First: if you see the prodrome, believe it immediately. A patient who says their lips feel funny after a block, or that their ears are ringing, or who has an odd metallic taste, is handing you the early warning the pharmacology built in. The correct response is not reassurance and it is not "let's carry on and see." It is to stop.
Second: the trigger has to be broader than the prodrome. Treat any unexplained neurological or cardiovascular change in a patient who has recently received local anesthetic as LAST until proven otherwise. Unexplained agitation. Unexplained drowsiness. Unexplained hypotension or bradycardia. Progressive, unexplained anything. You lose nothing by stopping and observing a patient who turns out to be fine, and an injector who is waiting for a textbook symptom before acting has set their threshold in the wrong place.
Timing: the number that surprises people
Onset timing is bimodal, and both modes matter to a facial injector.
In single-injection cases reviewed by ASRA, the median time from injection to first symptom was 52.5 seconds, with an interquartile range of 30 to 180 seconds, and a mean of 89 seconds. That pattern — symptoms in under a minute — indicates direct injection into an artery supplying the brain, or an intravascular bolus large enough to cause CNS symptoms even after first-pass clearance through the lungs.
But approximately 25% of cases described symptoms first appearing more than five minutes after injection, and one report described a sixty-minute delay. Presentation delayed by one to five minutes suggests intermittent intravascular injection or delayed tissue absorption.
This produces the single most actionable rule in the literature: a patient who has received a potentially toxic dose of local anesthetic should be monitored for at least 30 minutes after injection. Not watched from across the room while you chart. Monitored, by someone, with the patient in the building.
For most aesthetic block work the doses are nowhere near potentially toxic, and a thirty-minute mandatory hold is not a sensible universal policy. Apply it where it belongs: multi-site block sessions, scalp blocks, and any session where your running total climbed into a meaningful fraction of the calculated ceiling.
Why the facial injector is a special case
This is the section that should change your practice, and it is the reason a dose calculation alone does not protect you.
The FDA labelling for lidocaine contains a specific warning about the head and neck:
"Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed."
Read that again with facial blocks in mind. A small dose — a dose that is a trivial fraction of the patient's calculated ceiling — can produce full systemic toxicity in the head and neck, because an inadvertent intra-arterial injection in facial territory can carry drug retrograde into the cerebral circulation rather than diluting it through the systemic circuit.
The three facial foramina you target for blocks — supraorbital, infraorbital and mental — each transmit a neurovascular bundle. The nerve you are aiming at travels with an artery and a vein. That is not a reason to avoid these blocks; it is the reason the technique includes aspirating before injecting, injecting slowly and incrementally, and keeping the volume at each site small.
Note the consequence for the arithmetic. Piece eight in this cluster shows that a full set of facial field blocks uses roughly a fifth to a quarter of the ceiling in a healthy adult — a comfortable margin. That margin is protection against absorption-driven toxicity. It is not protection against intra-arterial injection. Two different failure modes, one of which the ceiling does not defend against at all. Injectors who have internalised "I'm well under the maximum, therefore this cannot be LAST" have made exactly the wrong inference.
Facial anatomy is also the point at which this cluster meets the vascular one: the same arterial territories that make retrograde flow possible are the ones behind the filler-related vascular events described in can Botox cause blindness. Different drug, same arterial architecture, same reason anatomy is taught as a map rather than a list — which is what Anatomical Based Aesthetics Training and Special Anatomical Cadaver Aesthetics Training exist to build.
What it looks like in your chair, and what else it could be
Recognition fails in practice not because injectors do not know the list, but because the early signs are indistinguishable from things that happen in aesthetic practice every week. Here is the differential, honestly drawn.
| What you observe | Could be LAST | More commonly is | What separates them |
|---|---|---|---|
| Patient feels faint, pale, sweaty, bradycardic | Yes — CV depressant phase | Vasovagal reaction | Vasovagal responds rapidly to supine positioning and legs up; LAST does not resolve and often progresses. Vasovagal is common at the sight of a needle, before or during injection |
| Patient is anxious, tremulous, tachycardic, palpitations | Yes — CNS excitatory phase | Epinephrine effect from an epinephrine-containing solution, or anxiety | Epinephrine effect peaks and resolves within minutes; it does not progress to confusion or slurred speech. If it is not settling, stop assuming |
| Patient becomes talkative, restless, oddly disinhibited | Yes — this is a classic prodromal sign | Being nervous | Disinhibition out of character, in a patient who has just received a block, is a LAST sign until you have a better explanation |
| Patient says their lips or tongue feel numb or tingly | Yes — the first sign | Local spread of the block itself | If it is outside the territory you blocked, or bilateral after a unilateral block, treat it as systemic |
| Ringing in the ears | Yes | Rarely anything else in this setting | Take it seriously immediately |
| Drowsiness, confusion, slurred speech | Yes | Premedication effect | If the patient had an oral anxiolytic, you have lost your cleanest early sign. Plan for that before you sedate |
| Metallic taste | Yes | Nothing in particular | Ask about it rather than waiting to be told |
Three practical consequences fall out of that table.
Ask, do not wait. The early symptoms are subjective. A patient who is being injected does not necessarily volunteer that their ears are ringing. Keep talking to the patient during and after block placement — partly because a patient who is answering you coherently is a patient whose CNS is intact, and partly because the content of the answers is your monitor.
Sedation blinds you. If the patient has taken an oral anxiolytic, drowsiness and confusion stop being informative. That is an argument for placing blocks before the sedative takes full effect where the sequence allows, and for a lower threshold to act when it does not.
Position and reassess anything that looks vasovagal. A vasovagal episode resolves. If it does not, your working diagnosis has to change.
Prevention is the part you control
The ASRA advisory is explicit that no single intervention reliably eliminates the risk, and that meticulous attention to detail is the most important asset. In an office aesthetic setting, that reduces to five habits.
- Aspirate before injecting, at every site. A negative aspiration does not exclude intravascular placement, but a positive one saves you.
- Inject incrementally and slowly. Small aliquots with a pause between them convert a single large intravascular bolus into a small one that declares itself before the rest is delivered. This is the highest-value habit on the list.
- Use the smallest effective dose and volume. One to two millilitres per foramen produces a block. More volume produces a haematoma and eats the ceiling.
- Calculate the ceiling before you start and keep a running total. Covered in full in the dose calculation article in this cluster.
- Consider epinephrine-containing solution where appropriate. It slows systemic absorption, lowering the peak plasma level for a given dose, and an abrupt tachycardia after a test aliquot is itself a marker of intravascular placement.
Two contextual notes. Maximum recommended doses are, as the literature bluntly puts it, a rough guideline at best — LAST has occurred at doses within the recommended range, and higher doses have been given without adverse effect. And the risk is not confined to formal nerve blocks: a significant proportion of reported LAST has followed simple local anesthetic infiltration, which is what most injectors are doing most of the time.
For scale: reported incidence after peripheral nerve blocks is on the order of 0.03%, or 0.27 per 1,000 blocks, though estimates range widely by study design. It is rare. It is also disproportionately severe — LAST has accounted for roughly one third of closed claims for death or brain damage associated with regional anesthesia in American Society of Anesthesiologists closed claims data. Rare and catastrophic is exactly the profile that justifies a written plan.
The first sixty seconds in an aesthetic office
This is the part that belongs to you, and it is deliberately short because it has to be executable by whoever is in the room.
- Stop injecting. Immediately. Do not finish the site.
- Call for help. Say the words "possible local anesthetic toxicity" out loud so that everyone in the building is working on the same problem.
- Give oxygen and support the airway. Hypoxia, hypercarbia and acidosis develop within a minute of the onset of convulsions and they make everything worse. Effective ventilation with oxygen is the single most important early intervention and may avert cardiac arrest.
- Activate EMS. Early, not after it declares itself. A practice that waits until the patient seizes has lost the interval it needed.
- Do not give any more local anesthetic, in any form, for any reason.
- Keep the patient monitored and do not discharge them. Symptoms can appear late, and a patient who has had a symptomatic episode requires a period of observation that an aesthetic office is not the right setting to supervise.
What the definitive treatment is — and where it is taught
I want to be explicit about a boundary here, because this is exactly the territory in which improvised content gets people hurt.
The faculty session behind this article covers recognition. It does not cover rescue. The definitive treatment protocol for LAST is published by the American Society of Regional Anesthesia and Pain Medicine, and I am citing it here rather than paraphrasing it, so that you know it exists and know where to find the authoritative version.
The ASRA Local Anesthetic Systemic Toxicity Checklist (2020, v1.1) directs: call for help; get the LAST rescue kit; consider the cardiopulmonary bypass team; consider administering lipid emulsion early; for seizure, ensure an adequate airway with a benzodiazepine preferred; for arrhythmia or hypotension, epinephrine at smaller than normal doses, starting below 1 mcg/kg; and avoid local anesthetics, beta-blockers, calcium channel blockers and vasopressin. It specifies 20% lipid emulsion dosing by weight band, a maximum lipid dose of 12 mL/kg, continuation of lipid emulsion for more than 15 minutes once haemodynamically stable, and observation for 2 hours after a seizure or 4 to 6 hours after cardiovascular instability. Its own headline warning is that LAST resuscitation is different from standard ACLS.
Two things follow, and both are decisions for the practice rather than for an article.
Whether your office stocks lipid emulsion and a LAST rescue kit is a question you should answer deliberately. An office that performs high-volume infiltration or extensive multi-site blocks is in a different position from one placing two millilitres for a lip block. Stocking it also means someone must be trained and credentialled to use it and it must be in date. A rescue kit nobody can lawfully or competently deploy is not a safety measure.
Do not learn this from reading. Recognition can be taught in writing. Managing a seizing or arrest patient cannot. That is taught hands-on, under supervision, with the drugs, the airway equipment and the team in the room — which is where it sits in Empire Medical Training's curriculum, alongside the high-volume injectable and scalp work in Complete Dermal Filler Training, Platelet Rich Plasma Training and Medical Hair Loss Treatment, PDO Threads & PRP Hair Restoration Training, where the volumes are largest and the margin smallest.
What to change on Monday
- Print the ASRA checklist and put it where the local anesthetic is stored. Not in a binder. On the wall.
- Add one sentence to your block procedure: aspirate, inject incrementally, and keep talking to the patient.
- Decide your observation rule and write it down — which sessions trigger a 30-minute monitored hold, and who does the monitoring.
- Brief the whole team on the prodrome, not just the injector. The person who hears "my ears are ringing" is often the assistant.
- Decide the rescue-kit question in writing, with a date, and review it annually.
- Rehearse the first sixty seconds once. Five minutes, out loud, as a team. It is the difference between a plan and a document.
The symptom cascade above reflects Dr. Jennifer Thomas-Goering's teaching in Empire Medical Training's hands-on curriculum. The epidemiology, atypical-presentation data, timing data and treatment checklist are sourced from the American Society of Regional Anesthesia and Pain Medicine's Practice Advisory on Local Anesthetic Systemic Toxicity, ASRA's 2020 LAST Checklist, and current FDA labelling, and are attributed accordingly rather than to her. Practice is scope- and state-dependent. Emergency management is learned under supervision; this article is educational and is not a substitute for training.
Dr. Jennifer Thomas-Goering, DO, MBA is a board-certified anesthesiologist, clinical lead instructor and executive committee member at Empire Medical Training, and founder of an aesthetics practice in Ann Arbor, Michigan.
Related guides in this cluster
Part of Injectable Anesthesia and Patient Comfort.
Clinical GuideBenzodiazepine or Clonidine? Choosing an Oral Anxiolytic for the Long Aesthetic AppointmentBenzodiazepine vs clonidine for pre-procedure anxiolysis — the mechanisms, the respiratory and scheduling differences, and the screenin
Clinical GuideSublingual Ketamine in the Aesthetic Suite: Where It Fits, and What It Costs YouSublingual ketamine is the wrong tool for toxin and the right one for higher-discomfort work. The pharmacology, the FDA position, and t
Clinical GuideNitrous Oxide in the Aesthetic Practice: Self-Titration, Contraindications and Same-Day DrivingNitrous oxide in aesthetic practice is the one non-controlled, self-limiting option. Titration range, contraindications, and the equipm
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore Complete Dermal Filler Training →Disclaimer
This article reflects the clinical opinions and experience of Dr. Jennifer Thomas-Goering, DO, MBA, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.